Compound 1309
Identifiers
- Canonical SMILES:
CC[C@H](N)C(=O)N[C@H]1[C@@H](CNC(=O)NCc2ccccc2)CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(c1ccccc1)c1ccccc1
- IUPAC name:
(3S,6S,7R,9aS)-6-[[(2S)-2-aminobutanoyl]amino]-N-benzhydryl-7-[(benzylcarbamoylamino)methyl]-5-oxo-1,2,3,6,7,8,9,9a-octahydropyrrolo[1,2-a]azepine-3-carboxamide
- InChi:
InChI=1S/C36H44N6O4/c1-2-29(37)33(43)41-32-27(23-39-36(46)38-22-24-12-6-3-7-13-24)18-19-28-20-21-30(42(28)35(32)45)34(44)40-31(25-14-8-4-9-15-25)26-16-10-5-11-17-26/h3-17,27-32H,2,18-23,37H2,1H3,(H,40,44)(H,41,43)(H2,38,39,46)/t27-,28+,29+,30+,32+/m1/s1
- InChiKey:
IHWAHCOLVXAEFK-HVSNEVFASA-N
External links
![]() 44237060 |
![]() CHEMBL582974 |
![]() 24642011 |
External search
![]() |
![]() |
![]() |
![]() |
![]() |
Bibliography (2)
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
2 | 1 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
XIAP / Smac | 6.62 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 624.34 g/mol | |||
HBA | 10 | |||
HBD | 6 | |||
HBA + HBD | 16 | |||
AlogP | 2.92 | |||
TPSA | 145.66 | |||
RB | 11 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
2 | 2 | 1 | 0 | 0 |
Pharmacological data
Bibliography | Name | Target | Competition | Assay type | Assay name | Cell line | Activity type | Activity |
---|---|---|---|---|---|---|---|---|
19620011 | 26b | XIAP P98170 |
|
Biochemical assay | Fluorescence Polarization | pIC50 (half maximal inhibitory concentration, -log10) | 6.62 | |
WO2009060292 | 32b | XIAP P98170 |
|
Biochemical assay | Fluorescence Polarization | pIC50 (half maximal inhibitory concentration, -log10) | 6.53 | |
19620011 | 26b | XIAP P98170 |
|
Cellular assay | Proliferation assay | MDA-MB-231 | pIC50 (half maximal inhibitory concentration, -log10) | 5.47 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.6613 | Neocitrullamon | DB13396 | |
0.6491 | D-phenylalanyl-N-benzyl-L-prolinamide | DB07143 | |
0.6404 | 3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide | DB07190 | |
0.6283 | N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide | DB06858 | |
0.6271 | D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide | DB07133 | |
0.6228 | N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide | DB06853 | |
0.6228 | (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide | DB07095 | |
0.6228 | (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide | DB07131 | |
0.6198 | 1-[3,3-Dimethyl-2-(2-Methylamino-Propionylamino)-Butyryl]-Pyrrolidine-2-Carboxylic Acid(1,2,3,4-Tetrahydro-Naphthalen-1-Yl)-Amide | DB02628 | |
0.6154 | Orvepitant | DB12427 | |
0.6140 | (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide | DB06850 | |
0.6106 | 1-[(2R)-2-aminobutanoyl]-N-(3-chlorobenzyl)-L-prolinamide | DB06878 | |
0.6106 | D-leucyl-N-(3-chlorobenzyl)-L-prolinamide | DB06911 | |
0.6106 | 1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide | DB06947 | |
0.6106 | D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide | DB06996 |